|
Index | - | P/E | - | EPS (ttm) | -0.39 | Insider Own | 14.40% | Shs Outstand | 38.13M | Perf Week | 1.26% |
Market Cap | 1.63B | Forward P/E | - | EPS next Y | -1.26 | Insider Trans | 40.58% | Shs Float | 32.92M | Perf Month | -3.11% |
Income | -14.90M | PEG | - | EPS next Q | -0.18 | Inst Own | 17.20% | Short Float | 2.16% | Perf Quarter | - |
Sales | - | P/S | - | EPS this Y | -96.40% | Inst Trans | - | Short Ratio | 3.74 | Perf Half Y | - |
Book/sh | - | P/B | - | EPS next Y | -22.30% | ROA | - | Target Price | 60.67 | Perf Year | - |
Cash/sh | 3.35 | P/C | 12.72 | EPS next 5Y | - | ROE | - | 52W Range | 35.73 - 60.27 | Perf YTD | -11.34% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -29.27% | Beta | - |
Dividend % | - | Quick Ratio | 24.50 | Sales past 5Y | - | Gross Margin | - | 52W Low | 19.31% | ATR | 2.76 |
Employees | 21 | Current Ratio | 24.50 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 46.14 | Volatility | 5.11% 6.42% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.36 | Prev Close | 41.86 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 190.16K | Price | 42.63 |
Recom | 1.50 | SMA20 | -4.46% | SMA50 | -6.50% | SMA200 | -6.50% | Volume | 68,573 | Change | 1.84% |
![]() | |||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. | |||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite